How many insider trades does FilingIQ track for ALGS?

FilingIQ tracks 71 Form 4 insider transactions for ALGS (Aligos Therapeutics, Inc.), covering filings from Oct 20, 2020 onwards. 4 of those were filed in the last 90 days.

Are ALGS insiders net buyers or net sellers?

Across the full Form 4 history for ALGS, 6 transactions (8%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ALGS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ALGS in?

Aligos Therapeutics, Inc. (ALGS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $46.58M.

ALGS insider trading

NasdaqCM Healthcare

Aligos Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

8% / 0%

Market cap

$46.58M

About Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Company website: www.aligos.com

ALGS insider activity at a glance

FilingIQ has scored 71 insider transactions for ALGS since Oct 20, 2020. The most recent filing in our index is dated Mar 9, 2026.

Across the full history, 6 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ALGS insider trades is 54.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ALGS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for ALGS?: FilingIQ tracks 71 Form 4 insider transactions for ALGS (Aligos Therapeutics, Inc.), covering filings from Oct 20, 2020 onwards. 4 of those were filed in the last 90 days.
Are ALGS insiders net buyers or net sellers?: Across the full Form 4 history for ALGS, 6 transactions (8%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ALGS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ALGS in?: Aligos Therapeutics, Inc. (ALGS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $46.58M.

Methodology & sources

Every ALGS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.